From Clinical Question to Testable Hypothesis: Using AI Co-Scientist to Identify Repurposable Drugs for Alpha-Gal Syndrome
Abstract
Abstract Alpha-gal syndrome (AGS) is a tick induced, IgE-mediated allergy to the mammalian carbohydrate galactose-alpha 1,3-galactose (alpha-gal), with rising incidence and no disease modifying therapy. We describe and critically appraise a physician in the loop workflow in which a practicing clinician used Google's AI co-scientist, a multi-agent system built on the Gemini model, accessed through the experimental Hypothesis Generation tool to generate and rank drug repurposing hypotheses for AGS. Through a structured natural-language interview, the clinician defined the therapeutic goal (durable, drug-free oral tolerance permitting mammalian-meat reintroduction) and five appraisal constraints (oral route; 3–6 month course; cost
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.